Erdafitinib(1), a novel small-molecule targeted agent, is the first fibroblast growth factor receptor(FGFR) tyrosine kinase inhibitor approved for the treatment of advanced or metastatic bladder cancer. By selectively targeting genetic alterations in FGFR signaling pathways(such as mutations, fusions, or amplifications), it modulates cellular growth and division, thereby treating urothelial carcinoma of bladder and demonstrating broad clinical and commercial application prospects. This review systematically analyzes the synthetic strategies of 1, comprehensively reviews 9 reported synthetic routes of 1, and critically evaluates the advantages and limitations of each route. These above-mentioned insights aim to offer valuable references and guidance for the synthesis research and industrial-scale manufacture of 1 and its key intermediates.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |